EXDENSUR (depemokimab-ulaa) is a revolutionary maintenance treatment specifically designed for individuals aged 12 and older who suffer from severe asthma with an eosinophilic phenotype. This innovative product offers a unique solution by only requiring two doses per year, helping to protect against asthma attacks and significantly reducing the frequency of asthma-related complications. EXDENSUR targets the underlying inflammation that leads to these attacks, proving effective in maintaining asthma control.

In addition to its robust treatment capabilities, EXDENSUR is supported by the EXDENSUR Copay Program, allowing eligible patients to manage their out-of-pocket expenses effectively, potentially paying as little as $0. Patients can access comprehensive resources to understand how to start their treatment and what side effects to anticipate. While it is crucial for patients to consult their healthcare providers before starting EXDENSUR, the brand is committed to empowering asthma patients with the support and information they need to navigate their treatment journey.